38
Participants
Start Date
March 16, 2021
Primary Completion Date
June 5, 2024
Study Completion Date
June 5, 2026
PRGN-2012 - Phase I; Dose Level 1
In Phase 1, dose level 1 of the clinical trial, PRGN-2012 is administered at 1 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
PRGN-2012 - Phase I; Dose Level 2
In Phase 1, dose level 2 of the clinical trial, PRGN-2012 is administered at 5 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
PRGN-2012 - Phase II; Dose Level 2
The Phase 2 portion is designed as a dose expansion study where patients are treated at the RP2D of 5 x 10\^11 PU.
National Institutes of Health Clinical Center, Bethesda
Lead Sponsor
National Cancer Institute (NCI)
NIH
Precigen, Inc
INDUSTRY